Medical Therapy of Genital Human Papilloma Virus-Related Disease

Van Ranst M Kaplan JB Burk RD. Phylogenetic classification of human papillomaviruses: Correlation with clinical manifestations. J Gen Virol 1992;73:2653–60.

Zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. In: Zur Hausen H , ed. Current Topics in Microbiology and Immunology, vol 186. Berlin: Springer, 1994;131–56.

Melkert PWJ Hopman E van den Brule AJC Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919–23.

Ponten J Adami H-O Bergstrom R Strategies for global control of cervical cancer. Int J Cancer 1995;60:1–26.

Stanley MA. Virus-kerarinocyte interactions in the infectious cycle. In: Stern PL Stanley MA , eds. Human Papillomavirus and Cervical Cancer—Biology and Immunology. Oxford: Oxford University Press, 1994;116–31.

Stoler MW Whitbeck A Wolinsky SM Infectious cycle of human papillomavirus type 11 in human foreskin xenografts in nude mice. J Virol 1990;64:3310–18.

Oriel JD. Natural history of genital warts. Br J Vener Dis 1971;47:1–13.

Kuo S-R Liu J-S Broker TR Chow LT. Cell-free replication of the human papillomavirus DNA with homologous viral E1 and E2 proteins and human cell extracts. J Biol Chem 1994;269:24058–65.

Kandel J Bossy-Wetzel E Radvanyi F Klagsbrun M Folkman J Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991;66:1095–104.

Arbeit JM Munger K Howley PM Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 1994;68:4358–68.

Coleman N Birley HDL Renton AM Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768–74.

Riva JM Sedlack TV Cunnane MF Mangan CE. Extended carbon dioxide laser vaporisation in the treatment of subclinical papillomavirus infection of the lower genital tract. Obstet Gynecol 1989;73:25–30.

Krebs H-B Helmkamp BF. Treatment failure of genital condylomata acuminata in women: Role of the male sexual partner. Am J Obstet Gynecol 1991;165:337–9.

Krebs H-B Helmkamp BF. Does the treatment of genital condylomata in men decrease the treatment failure rate of cervical dysplasia in the female sexual partner? Obstet Gynecol 1990;76:660–3.

Kaplan IW. Condylomata acuminata. New Orleans Med Surg J 1942;94:388–90.

Sullivan M King IS. Effects of resin of podophyllin on normal skin, condylomata acuminata and Verrucae vulgares. Arch Dermatol Syph 1947;56:30–45.

Murphy M Bloom GD. Podophyllin or podophyllotoxin as treatment for condylomata acuminata? Papillomavirus Rep 1991;2:87–9.

Fraser PA Lacey CJN Maw RD. Motion: Podophyllotoxin is superior to poidophyllin in the treatment of genital warts. J Eur Acad Dermatol Venereal 1993;2:328–34.

von Krogh G Maibach HI. Cutaneous cytodestructive potency of lignans. I. A comparative evaluation of influence on epidermal and dermal DNA synthesis and on dermal microcirculation in the hairless mouse. Arch Dermatol Res 1982;274:9–20.

Lassus A. Comparison of podophyllotoxin and podophyllin in the treatment of genital warts, Lancet 1987;ii:512–3.

Edwards A Atma-Ram A Thin RN. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin Med 1988;64:263–5.

Kinghorn GR McMillan A Mulcahy F Drake S Lacey C Bingham JS. An open, comparative study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllin solution in the treatment of condyloma acuminata in males and females. Int J STD AIDS 1993;4:194–9.

Hellberg D Svarrer T Nilsson S Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline®) vs weekly applications of 20% podophyllin solution. Int J STD AIDS 1995;6:257–61.

Godley MJ Bradbeer CS Gellan M Thin RNT. Cryotherapy compared with trichloracetic acid in treating genital warts. Genitourin Med 1987;63:390–2.

Abdullah AN Walzman M Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloracetic acid. Sex Transm Dis 1993;20:344–5.

Thompson JPS Grace RH. The treatment of perianal and anal condylomata: A new operative technique. J R Soc Med 1978;71:180–5.

Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985;ii:1146–8.

Scoular A. Choosing equipment for treating genital warts in genitourinary medicine clinics. Genitourin Med 1991;67:413–9.

Prendiville W Cullimore J Norman S. Large loop excision of transformation zone (LLETZ). A new method of management for women with cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1989;96:1054–60.

Bigrigg A Haffenden DK Sheehan AC Codling BW Read MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet 1994;343:32–4.

Stone K Becker T Hadgu A Kraus S. Treatment of external genital warts: A randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990;66:16–9.

Kraus SJ Stone KM. Management of genital infections caused by human papillomavirus. Rev Infect Dis 1990;12:5620–32.

Douglas JM Eron LJ Judson FN A randomised trial of combination therapy with intralesional interferon-α_2b, and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis 1990;162:52–9.

The Condyloma International Collaborative Study Group. Randomised placebo-controlled double-blind combined therapy with laser surgery and systemic interferon-α_2a in the treatment of anogenital condylomata acuminata. J Infect Dis 1993;167:824–9.

Bonnez W Oakes D Bailey-Farchione A A randomised, double-blind, placebo-controlled trial of systemically administered interferon-α, -β or -γ in combination with cryotherapy for treatment of condylomata acuminata. J Infect Dis 1995;171:1081–9.

Biberstein J. Versuche uber immunotherapie der warzen und kondylome. Klin Wochenschr 1925;4:638–41.

Malison MD Morris R Jones LW. Autogenous vaccine therapy for condyloma acuminatum. A double-blind controlled study. Br J Vener Dis 1982;58:62–7.

Campo MS. Towards vaccines against papillomavirus. In: Stern PL Stanley MA , eds. Human Papillomaviruses and Cervical Cancer. Biology and Immunology. Oxford: Oxford University Press, 1994;177–91.

Reynolds M Murphy M Waugh MA Lacey CJN. An audit of treatment of genital warts: Opening the feedback loop. Int J STD AIDS 1993;4:226–31.

Lorincz AT Reid R Jenson AB Greenberg MD Lancaster WD Kurman RJ. Human papillomavirus infection of the cervix: Relative risk associations of fifteen common ano-genital types. Obstet Gynecol 1992;79:328–37.

Remmink AJ Walboomers JMM Heimerhorst TJM The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995;61:306–11.

Kataja V Syrjanen K Mantyjarvi R Prospective follow-up of cervical HPV infections; lifetable analysis of histopathological, cytological and colposcopic data. Eur J Epidemiol 1989;5:1–7.

Tidbury P Singer A Jenkins D. CIN 3: The role of lesion size in invasion. Br J Obstet Gynaecol 1992;99:583–6.

De Aloyslo D Miliffi L Iannicelli T Penacchioni P Bottiglioni F. Intramuscular interferon-β treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection. Acta Obstet Gynecol Scand 1994;73:420–4.

Meyskens FL Surwit E Moon TE Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomised trial. J Natl Cancer Inst 1994;86:539–43.